Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results in the French cohort. Methods— One thousand seventy-three French patients were assigned to <70 mg/dL (1.8 mmol/L) and 1075 to 100±10 mg/dL (90–110 mg/dL, 2.3–2.8 mmol/L). To achieve these goals, investigators used the statin and dosage of their choice and added ezetimibe on top if needed. The primary outcome was the composite of ischemic stroke, myocardial infarction, new symptoms requiring urgent coronary or carotid revascularization and vascular death. Results— After a median follow-up of 5.3 years, the achieved LDL cholesterol was 66 (1.69 mmol/L) and 96 mg/dL (2.46 mmol/L) on average, respectively. The primary end point occurred in 9.6% and 12.9% of patients, respectively (HR, 0.74 [95% CI, 0.57–0.94]; P =0.019). Cerebral infarction or urgent carotid revascularization following transient ischemic attack was reduced by 27% ( P =0.046). Cerebral infarction or intracranial hemorrhage was reduced by 28% ( P =0.023). The primary outcome or intracranial hemorrhage was reduced by 25% ( P =0.021). Intracranial hemorrhages occurred in 13 and 11 patients, respectively (HR, 1.17 [95% CI, 0.53–2.62]; P =0.70). Conclusions— After an ischemic stroke of documented atherosclerotic origin, targeting a LDL cholesterol of <70 mg/dL during 5.3 years avoided 1 subsequent major vascular event in 4 (number needed to treat of 30) and no increase in intracranial hemorrhage. Registration— URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01252875.
Cet article s'interroge sur l'adéquation de la théorie de la terminologie en relation avec les pratiques actuelles de la discipline et propose quatre hypothèses reposant sur des études conduites en biotechnologie et en bioinformatique. L'auteur démontre que les termes sont bien des signes linguistiques. Ils en sont cependant différents car leur sens est réglé par un contexte linguistique et pragmatique tout autant que par un système conceptuel. La tâche désormais dévolue à la terminologie est de comprendre la nature linguistique des contextes spécialisés afin d'être en mesure d'analyser le sens des termes.This paper calls into question the theory of terminology and proposes four hypotheses based on the study of specialized lexicons in biotechnology and biocomputing. It shows that the actual task of terminology is to understand the linguistic nature of the specialized context and the way the meaning is constructed. It concludes that terms are linguistic signs but are different from them not because they are monosemic by nature but because their meaning is constrained by their specialized linguistic and pragmatic context as much as by their conceptual domain
We present in this paper a model of derivation encoded by means of Lexical Functions (Mel’č uk et al. 1984–1999, Mel’čuk et al. 1995, Wanner 1996). It is based on semantic derivation as in the Explanatory and Combinatorial Lexicology, but we examine the category of morphological derivatives in order to organize sets of derivatives around a key term. Lexical functions express linguistic relations between words and allow a rigorous encoding. We use Standard Lexical functions and also discuss the usefulness of non-standard Lexical Function such as {avant}, {à distance}, {réciprocité} for the specific needs of some derivatives found in the corpus. We describe the structuration of such a terminology for the purpose of a specialized dictionary.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.